Since the identification of the cystic fibrosis gene (CFTR),' more than 265 mutations have been described (CF Genetic Analysis Consortium, 1992 This brings the number of cases with limb/pelvis-hypoplasia/aplasia syndrome (LPHAS) to nine (five female and four male). This total includes one case from Brazil4 and the three sibs from Israel.' Among these five sibships, the three sets of parents were first cousins or double first cousins.'35 I was delighted to see these reports because they provided further proof (as I believe) that the private syndrome does not exist. Often many 'new' syndromes are referred to as 'private' particularly if they are first described in the third world. So called 'private' syndromes may in fact be previously unrecognised or unreported and yet be 'relatively common' in certain populations. The absence of known parental consanguinity in two families with LPHAS could imply that the gene frequency in the relevant population may not be very low.
I wish to report further data on one of the original patients who was re-evaluated at the age of 18 (in 1990) because of absent menarche. Her breasts and other secondary sexual characteristics had developed by the age of 15 years. She and her parents were not particularly anxious about her fertility because of her severe handicap. They wanted to be sure that there were no life threatening consequences of the disease. Her FSH, LH, and prolactin levels were normal. Ultrasonography showed apparently normal ovaries and absent uterus. This was confirmed by another ultrasonographer. It was not possible to perform pelvic examinations because of virginity. Laparoscopic examination was declined.
These data indicate normal gonadal development in a female and support the finding of Farag et all of uterus hypoplasia/ aplasia. Such findings in two out of five reported females suggest that it is not fortuitous and is probably a variable manifestation of LPHAS that should be considered in future cases.
From a nosological perspective, LPHAS is an appropriate descriptive designation.
However, in the light of the mullerian hypoplasia/aplasia, the term limb/pelvis/uterushypoplasia/aplasia may be a more precise name. Three of the five reports have used the respective authors' names for syndrome identification.' 25 To avoid confusion, I suggest the use of the name of the first reporting author followed by a brief description of the major components. Considering the expansion in the number of new reported syndromes, this policy would make for easier cataloguing of genetic disorders.
